HARTFORD–U.S. Senator Chris Murphy (D-Conn.) announced that CYduct Diagnostics, Inc. (CYduct), based in Westport, was named April’s “Innovator of the Month.” CYduct’s mission is to simplify early breast cancer detection and improve clinical decisions and health outcomes for women. The company is developing for commercialization the first personalized proteomic test for breast cancer risk assessment – B-FIRST™. CYduct’s product aims to help women, physicians, and healthcare professionals accurately test for high-risk biomarkers that forecast the onset of breast cancer. The primary patient groups targeted by CYduct are known high risk women, and women with dense breast tissue, which is estimated to impact more than 45 million women in the U.S. alone. CYduct's personalized risk assessment test would help decrease the unacceptable high rates of false positives and false negatives in current risk assessment and screening tests.

“Early detection and personalized care can be lifesaving for women impacted by breast cancer. The team at CyDuct Diagnostics is doing important work to make that a reality. I’m proud to recognize their innovative approach, and look forward to watching the company continue to grow in Connecticut,” said Murphy.

"We are delighted that CYduct Diagnostics was named 'Innovator of the Month' by Senator Chris Murphy. Our goal from the beginning was to not only make a difference in the lives of women everywhere by providing them with the tools they need to take control of their breast health, but also by fostering our growth within the rich, innovative ecosystem in our home state of Connecticut,” said Dom Gatto, CEO of CYduct Diagnostics.

Murphy believes entrepreneurship and innovation are the building blocks for a strong economy. In the U.S. Senate, he has introduced legislation to incentivize angel investors to put more money into startup companies—the Angel Tax Credit Act. Startup companies create an average of 2 million jobs each year.

###